New combo therapy tested for Hard-to-Treat cancers
NCT ID NCT00479128
First seen Nov 01, 2025 · Last updated Jun 12, 2026 · Updated 41 times
Summary
This early-phase study aims to find the highest safe dose of a chemotherapy combination (gemcitabine and doxorubicin) when given with the targeted drug bortezomib. It includes up to 80 adults with advanced urothelial cancer or other solid tumors that cannot be removed by surgery. The goal is to control the disease by identifying a tolerable dose for future studies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Texas MD Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.